Literature DB >> 22695340

Alternative normalization methods demonstrate widespread cortical hypometabolism in untreated de novo Parkinson's disease.

V Berti1, C Polito, P Borghammer, S Ramat, L Mosconi, E Vanzi, M T De Cristofaro, M De Leon, S Sorbi, A Pupi.   

Abstract

AIM: Previous positron emission tomography (PET) [18F]fluorodeoxyglucose ([18F]FDG) studies in Parkinson's disease (PD) demonstrated that moderate to late stage patients display widespread cortical hypometabolism, whereas early stage PD patients exhibit little or no cortical changes. However, recent studies suggested that conventional data normalization procedures may not always be valid, and demonstrated that alternative normalization strategies better allow detection of low magnitude changes. We hypothesized that these alternative normalization procedures would disclose more widespread metabolic alterations in de novo PD.
METHODS: [18F]FDG PET scans of 26 untreated de novo PD patients (Hoehn & Yahr stage I-II) and 21 age-matched controls were compared using voxel-based analysis. Normalization was performed using gray matter (GM), white matter (WM) reference regions and Yakushev normalization.
RESULTS: Compared to GM normalization, WM and Yakushev normalization procedures disclosed much larger cortical regions of relative hypometabolism in the PD group with extensive involvement of frontal and parieto-temporal-occipital cortices, and several subcortical structures. Furthermore, in the WM and Yakushev normalized analyses, stage II patients displayed more prominent cortical hypometabolism than did stage I patients.
CONCLUSION: The use of alternative normalization procedures, other than GM, suggests that much more extensive cortical hypometabolism is present in untreated de novo PD patients than hitherto reported. The finding may have implications for our understanding of the basic pathophysiology of early-stage PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22695340      PMCID: PMC3846292     

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  35 in total

1.  A unified statistical approach for determining significant signals in images of cerebral activation.

Authors:  K J Worsley; S Marrett; P Neelin; A C Vandal; K J Friston; A C Evans
Journal:  Hum Brain Mapp       Date:  1996       Impact factor: 5.038

2.  Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization.

Authors:  Per Borghammer; Joel Aanerud; Albert Gjedde
Journal:  Neuroimage       Date:  2009-03-19       Impact factor: 6.556

3.  Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET.

Authors:  G Berding; P Odin; D J Brooks; G Nikkhah; C Matthies; T Peschel; M Shing; H Kolbe; J van Den Hoff; H Fricke; R Dengler; M Samii; W H Knapp
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

4.  FDG PET in the differential diagnosis of parkinsonian disorders.

Authors:  Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg
Journal:  Neuroimage       Date:  2005-04-26       Impact factor: 6.556

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease.

Authors:  Y Imon; H Matsuda; M Ogawa; D Kogure; N Sunohara
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

8.  Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia.

Authors:  N I Bohnen; S Minoshima; B Giordani; K A Frey; D E Kuhl
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

9.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

10.  Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease.

Authors:  Cindy Casteels; Erwin Lauwers; Guy Bormans; Veerle Baekelandt; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-29       Impact factor: 9.236

View more
  5 in total

Review 1.  Mechanisms of deep brain stimulation.

Authors:  Todd M Herrington; Jennifer J Cheng; Emad N Eskandar
Journal:  J Neurophysiol       Date:  2015-10-28       Impact factor: 2.714

Review 2.  Brain Glucose Hypometabolism and Iron Accumulation in Different Brain Regions in Alzheimer's and Parkinson's Diseases.

Authors:  Indira Y Rao; Leah R Hanson; Julia C Johnson; Michael H Rosenbloom; William H Frey
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-29

3.  Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET.

Authors:  Juergen Dukart; Robert Perneczky; Stefan Förster; Henryk Barthel; Janine Diehl-Schmid; Bogdan Draganski; Hellmuth Obrig; Emiliano Santarnecchi; Alexander Drzezga; Andreas Fellgiebel; Richard Frackowiak; Alexander Kurz; Karsten Müller; Osama Sabri; Matthias L Schroeter; Igor Yakushev
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

4.  A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults.

Authors:  Sepideh Shokouhi; William R Riddle; Hakmook Kang
Journal:  Clin Interv Aging       Date:  2017-12-14       Impact factor: 4.458

5.  FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.

Authors:  Dawn C Matthews; Hedva Lerman; Ana Lukic; Randolph D Andrews; Anat Mirelman; Miles N Wernick; Nir Giladi; Stephen C Strother; Karleyton C Evans; Jesse M Cedarbaum; Einat Even-Sapir
Journal:  Neuroimage Clin       Date:  2018-08-10       Impact factor: 4.881

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.